Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael LaValley

Showing results (1-10 of 71) with videos related to

Pageof 8
Sort By:
Pharmaceutical Statistics|February 21, 2012
One-sample and two-sample analysis of heterogeneous person-time data in clinical trialsJing Xu, Michael LaValley
Journal of Thyroid Research|November 5, 2010
Prognostic outcomes of tall cell variant papillary thyroid cancer: a meta-analysisScharukh Jalisi, Tiffiny Ainsworth, Michael Lavalley
Graefe'S Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie|July 29, 2010
Meta-analysis and review on the effect of bevacizumab in diabetic macular edemaSunali Goyal, Michael Lavalley, Manju L Subramanian
JAMA|April 18, 2013
Vitamin D supplementation in patients with osteoarthritis--replyTimothy McAlindon, Michael LaValley, Bess Dawson-Hughes
American Journal of Physical Medicine & Rehabilitation|December 22, 2010
Do unblinded assessors bias muscle strength outcomes in randomized controlled trials of progressive resistance strength training in older adults?Chiung-ju Liu, Michael LaValley, Nancy K Latham
Contemporary Clinical Trials Communications|April 27, 2018
Extensions of the mTPI and TEQR designs to include non-monotone efficacy in addition to toxicity for optimal dose determination for early phase immunotherapy oncology trialsRevathi Ananthakrishnan, Stephanie Green, Daniel Li, et al.
Contemporary Clinical Trials Communications|December 5, 2019
2D (2 Dimensional) TEQR design for Determining the optimal Dose for safety and efficacyRevathi Ananthakrishnan, Stephanie Green, Daniel Li, et al.
ACR Open Rheumatology|January 28, 2022
ReplyDavid Felson, Michael LaValley, Diane Lacaille, et al.
JAMA|December 18, 2003
Intra-articular hyaluronic acid in treatment of knee osteoarthritis: a meta-analysisGrace H Lo, Michael LaValley, Timothy McAlindon, et al.
The American Journal of Medicine|October 27, 2004
Effectiveness of glucosamine for symptoms of knee osteoarthritis: results from an internet-based randomized double-blind controlled trialTimothy McAlindon, Margaret Formica, Michael LaValley, et al.
Pageof 8

Showing results (1-10 of 71) with videos related to

Sort By:
Pageof 8
Pharmaceutical Statistics|February 21, 2012
One-sample and two-sample analysis of heterogeneous person-time data in clinical trialsJing Xu, Michael LaValley
Journal of Thyroid Research|November 5, 2010
Prognostic outcomes of tall cell variant papillary thyroid cancer: a meta-analysisScharukh Jalisi, Tiffiny Ainsworth, Michael Lavalley
Graefe'S Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie|July 29, 2010
Meta-analysis and review on the effect of bevacizumab in diabetic macular edemaSunali Goyal, Michael Lavalley, Manju L Subramanian
JAMA|April 18, 2013
Vitamin D supplementation in patients with osteoarthritis--replyTimothy McAlindon, Michael LaValley, Bess Dawson-Hughes
American Journal of Physical Medicine & Rehabilitation|December 22, 2010
Do unblinded assessors bias muscle strength outcomes in randomized controlled trials of progressive resistance strength training in older adults?Chiung-ju Liu, Michael LaValley, Nancy K Latham
Contemporary Clinical Trials Communications|April 27, 2018
Extensions of the mTPI and TEQR designs to include non-monotone efficacy in addition to toxicity for optimal dose determination for early phase immunotherapy oncology trialsRevathi Ananthakrishnan, Stephanie Green, Daniel Li, et al.
Contemporary Clinical Trials Communications|December 5, 2019
2D (2 Dimensional) TEQR design for Determining the optimal Dose for safety and efficacyRevathi Ananthakrishnan, Stephanie Green, Daniel Li, et al.
ACR Open Rheumatology|January 28, 2022
ReplyDavid Felson, Michael LaValley, Diane Lacaille, et al.
JAMA|December 18, 2003
Intra-articular hyaluronic acid in treatment of knee osteoarthritis: a meta-analysisGrace H Lo, Michael LaValley, Timothy McAlindon, et al.
The American Journal of Medicine|October 27, 2004
Effectiveness of glucosamine for symptoms of knee osteoarthritis: results from an internet-based randomized double-blind controlled trialTimothy McAlindon, Margaret Formica, Michael LaValley, et al.
Pageof 8